18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
NCT06937112 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2025-04-22
Summary
Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.
Conditions
Interventions
- OTHER
-
PET-CT examination
Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination
Sponsors & Collaborators
-
Nanjing First Hospital, Nanjing Medical University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-10
- Primary Completion
- 2026-01-31
- Completion
- 2026-03-31
Countries
- China
Study Locations
More Related Trials
-
FAPI PET/CT in Various FAP-Related Disease Patients
NCT06688071 ·Status: RECRUITING
-
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer
NCT06614062 ·Status: COMPLETED
-
Clinical Study of 18F-FAPI-RGD in Breast Tumors
NCT05976620 ·Status: COMPLETED
-
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
NCT05030597 ·Status: RECRUITING
-
68Ga-FAPI PET/CT in Malignant Tumors
NCT05034146 ·Status: RECRUITING ·Phase: NA
-
[18F]FAPI PET/CT in Suspicious Focal Liver Lesions Without FDG Avidity
NCT05806333 ·Status: UNKNOWN ·Phase: NA
-
Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
NCT05749302 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
NCT06107608 ·Status: RECRUITING ·Phase: NA
-
18F-FAPI PET/CT in Patients With Various Types of Cancer
NCT05810324 ·Status: UNKNOWN ·Phase: NA
-
Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI
NCT05400967 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
NCT05121779 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer
NCT06916338 ·Status: RECRUITING
-
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies
NCT05506566 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
NCT06270394 ·Status: COMPLETED ·Phase: NA
-
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
NCT04813705 ·Status: RECRUITING ·Phase: PHASE2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
NCT06503146 ·Status: RECRUITING ·Phase: PHASE2
-
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
NCT06734572 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
NCT06638034 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Malignant Tumors
NCT04554719 ·Status: UNKNOWN ·Phase: NA
-
Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors
NCT06182644 ·Status: RECRUITING ·Phase: NA
-
Clinical Study of 18F -FAPI-RGD in Renal Tumor
NCT05976607 ·Status: COMPLETED
-
Clinical Translation of a Novel FAPI Dimer [68Ga]Ga-LNC1013
NCT06159049 ·Status: COMPLETED
-
18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor
NCT06126705 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG
NCT05543317 ·Status: COMPLETED ·Phase: NA
-
A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
NCT05990998 ·Status: COMPLETED ·Phase: PHASE1/PHASE2